FDA panel backs label changes to DPP-4 inhibitors

FDA's Endocrinologic and Metabolic Drugs Advisory Committee recommended on Tuesday that the agency add language about potential risks of heart failure to the labels of two DPP-4 inhibitors to treat diabetes -- Onglyza saxagliptin from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Nesina alogliptin from Takeda

Read the full 440 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers